Phio Pharmaceuticals Corp. is a clinical-stage biotechnology company. The Company's INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. It is developing therapeutics that are designed to leverage INTASYL to target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. The Company's pipeline is focused on the treatment of cutaneous Squamous Cell Carcinoma (cSCC) and melanoma. Its product pipeline includes PH-762 and PH-894. PH-762 is an INTASYL compound designed to reduce the expression of cell death protein 1 (PD-1). PD-1 is a protein that inhibits T cellsâ€™ ability to kill cancer cells and is a clinically validated target in immunotherapy. PH-894 is an INTASYL compound that is designed to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, thereby affecting the immune system as well as the tumor.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-02	US$0.9950	-0.50%	25,678
26-10-01	US$1.000	-2.91%	50,259
26-09-30	US$1.030	0.00%	103,992
26-09-29	US$1.030	+1.98%	82,153
26-09-28	US$1.010	0.00%	112,280

Delayed Quote Nasdaq

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.000USD

Average target price

14.00USD

Spread / Average Target

+1,300.00%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed Nasdaq 12:49:16 2026-10-02 EDT			5-day change	1st Jan Change
0.9950 ^USD	-0.50%		-1.49%	-5.24%

09-14	Phio Pharmaceuticals Corp Submits Materials To FDA Supporting Next Stage Of Clinical Development For PH-762 In Cutaneous Squamous Cell Carcinoma	CI
08-06	Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Market Cap	11.62M 10.32M 9.63M 8.78M 16.56M 1.12B 16.71M 117M 45.18M 571M 43.62M 42.67M 1.83B	P/E 2026 *	-0.69x	P/E 2027 *	-1.64x
Enterprise Value	11.62M 10.32M 9.63M 8.78M 16.56M 1.12B 16.71M 117M 45.18M 571M 43.62M 42.67M 1.83B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	96.58%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq	PHIO	Delayed
CBOE	PHIO	Real-time

09-14	Phio Pharmaceuticals Corp Submits Materials To FDA Supporting Next Stage Of Clinical Development For PH-762 In Cutaneous Squamous Cell Carcinoma	CI
08-06	Phio Pharmaceuticals Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-21	Phio Pharmaceuticals Corp. Appoints R. Todd Plott to its Board and Governance Committee, Effective July 20, 2026	CI
07-15	Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision	CI
06-24	Phio Pharmaceuticals Corp. Announces the Manufacture of the First Commercial-Scale Cgmp Batch of Ph-762 Drug Substance Has Commenced At Nitto Denko Avecia, Inc	CI
05-07	Phio Pharmaceuticals Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-08	Phio Pharmaceuticals Corp - Enters at the Market Offering Agreement with H.C. Wainwright on April 8, 2026	RE
03-30	Phio Pharmaceuticals Corp Announces Agreement With U.S. cGMP Manufacturing Source For Drug Product PH-762	CI
03-05	Phio Pharmaceuticals Corp. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-23	Phio Pharmaceuticals Corp. Promotes Jennifer Phillips, Pharm.D., to Senior Vice President	CI
02-10	Phio Pharmaceuticals Corp. Announces Safety Monitoring Committee's Positive Wrap-Up on Lead Clinical Candidate PH-762 in Skin Cancer Trial	CI
01-20	Phio Pharmaceuticals Corp announces key tumor response data from PH-762 trial	RE
01-20	Phio Pharmaceuticals Announces Key Tumor Response Data from All Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial	CI

Phio Pharmaceuticals Corp. Stock

Stocks

PHIO

US71880W5013

Biotechnology & Medical Research

Valuation: Phio Pharmaceuticals Corp.

Chart: Phio Pharmaceuticals Corp.

Latest news: Phio Pharmaceuticals Corp.

Analysts' recommendations: Phio Pharmaceuticals Corp.

Press Releases: Phio Pharmaceuticals Corp.

Quotes and Performance

Price Extremes

Managers and Directors: Phio Pharmaceuticals Corp.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

25-10-31	Phio Pharmaceuticals Corp. Announces Resignation of Robert Ferrara as Lead Independent Director of the Board and Compensation Committee and the Audit Committee, Effective October 31, 2025	CI
24-02-06	HC Wainwright Adjusts Price Target on Phio Pharmaceuticals to $4 From $6, Keeps Buy Rating	MT
21-06-14	Phio Pharmaceuticals : HC Wainwright Adjusts Phio Pharmaceuticals' Price Target to $6 From $4, Keeps Buy Rating	MT

09-23	Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference	NE
09-14	Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell Carcinoma	NE
09-11	Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	NE
08-11	Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894	NE
08-06	Phio Pharmaceuticals : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU

1 day	-0.70%
1 week	-1.49%
Current month	-3.40%
1 month	-11.95%
3 months	-0.50%
6 months	-22.27%
Current year	-5.24%

1 week	0.99	1.07
1 month	0.98	1.14
Current year	0.81	1.88
1 year	0.81	4.19
3 years	0.81	29.07
5 years	0.81	261.36
10 years	0.81	174,042.17

Manager	Title	Age	Since
Robert Bitterman CEO	Chief Executive Officer	75	-
Lisa Carson DFI	Director of Finance/CFO	60	2025-05-11
Mary Spellman CTO	Chief Tech/Sci/R&D Officer	64	-

Director	Title	Age	Since
Robert Bitterman CHM	Chairman	75	2013-04-29
Curtis Lockshin BRD	Director/Board Member	65	2013-04-17
Jonathan Freeman BRD	Director/Board Member	58	2017-06-06

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/29/26	R. Plott	Buy	Director	5,000	0.0430%
9/28/26	Lisa Carson	Free	Chief Financial Officer	108,000	0.9297%
9/28/26	Robert Bitterman	Free	Chief Executive Officer	400,000	3.4432%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PHIO PHARMACEUTICALS CORP.	-0.50%	-1.49%	-58.37%	-92.73%	11.62M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.41B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	59.26B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.14B
IQVIA HOLDINGS INC.	-1.19%	-4.74%	+26.04%	+32.85%	42.91B
REVOLUTION MEDICINES, INC.	+0.38%	+0.76%	+351.90%	+689.15%	44.13B
BEONE MEDICINES AG	-1.58%	-2.05%	+2.40%	+98.01%	40.79B
CELLTRION, INC.	-0.54%	+2.93%	+9.50%	+50.41%	30.77B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+5.11%	+33.11%	+19.50%	29.31B
INSMED INCORPORATED	+0.44%	-7.60%	-28.53%	+330.47%	23.71B
Average	-0.38%	-0.78%	+41.16%	+133.09%	39.25B
Weighted average by Cap.	-0.03%	-0.40%	+57.34%	+149.91%

	2026 *	2027 *
Net sales	-	-
Net income	-16.99M -15.1M -14.09M -12.85M -24.23M -1.63B -24.45M -171M -66.09M -835M -63.81M -62.42M -2.68B	-16.56M -14.72M -13.74M -12.52M -23.61M -1.59B -23.83M -166M -64.41M -814M -62.19M -60.84M -2.61B
Net Debt	-	-